News & Opinion
Top 10 Innovations
Cell & Molecular Biology
Disease & Medicine
Ecology & Environment
Genetics & Genomics
Pharma & Biotech
Image of the Day
Tanya Lewis | Apr 11, 2016
An analysis of the genomes of nearly 600,000 healthy individuals reveals a handful of people who appear resistant to certain genetic disorders.
GWAS IDs “Morning People”
Catherine Offord | Feb 4, 2016
In a large genome-wide association study, researchers from 23andMe locate 15 DNA regions associated with people’s preferences for early morning starts.
Following FDA OK, 23andMe to Expand Health Prediction
Kerry Grens | Oct 21, 2015
The personal genomics firm is ramping up its suite of disease-related genetic tests.
23andMe Enters Drug Development
Kerry Grens | Mar 12, 2015
The personal genomics firm announces plans to make medicines.
FDA OKs 23andMe Test
Kerry Grens | Feb 20, 2015
The US Food and Drug Administration will allow the personal genomics company to resume a disease-risk analysis.
23andMe Partners with Pfizer
Jef Akst | Jan 13, 2015
The personal genomics company strikes yet another deal to glean biomedically relevant information from its user data.
23andMe, Genentech Partner on Parkinson’s
Tracy Vence | Jan 7, 2015
Firms enter a multi-year deal for the analysis of whole-genome sequence data, with an eye toward drug discovery for Parkinson’s disease.
23andMe Expands to U.K.
Kerry Grens | Dec 2, 2014
British consumers can buy the genetic testing-associated health prediction service forbidden by the US government.
Abby Olena | Jan 14, 2014
Another personal genomics company faces government pressure—this time from the Federal Trade Commission.
23andMe Steps Back
Abby Olena | Dec 6, 2013
The company announces that it will stop offering health interpretations of personal genetic data.